Find Clinical Trial

Home » Find Clinical Trials » A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in combination with various standard treatments including hormonal and cytotoxic agents

A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in combination with various standard treatments including hormonal and cytotoxic agents

← Back

Study Phase	Phase 1-2

Therapeutic Area	Cancers

Indication	Solid tumors

Sponsor	Institut de Recherches Internationales Servier

Active substance/ Medical device	S064315

Active Substance Code	S064315

Protocol Code	CL1-64315-003

EudraCT Code	2019-000998-23

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.